CN115368332B - 6-芳/烷硫基-2h-吡喃-3-酮类化合物的合成方法及其应用 - Google Patents
6-芳/烷硫基-2h-吡喃-3-酮类化合物的合成方法及其应用 Download PDFInfo
- Publication number
- CN115368332B CN115368332B CN202211007274.4A CN202211007274A CN115368332B CN 115368332 B CN115368332 B CN 115368332B CN 202211007274 A CN202211007274 A CN 202211007274A CN 115368332 B CN115368332 B CN 115368332B
- Authority
- CN
- China
- Prior art keywords
- pyran
- alkylthio
- aryl
- reaction
- tert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001308 synthesis method Methods 0.000 title claims description 5
- -1 dihydropyrone compound Chemical class 0.000 claims abstract description 43
- 238000006243 chemical reaction Methods 0.000 claims abstract description 39
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000003054 catalyst Chemical class 0.000 claims abstract description 19
- 239000002904 solvent Substances 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 239000003208 petroleum Substances 0.000 claims abstract description 11
- 238000004440 column chromatography Methods 0.000 claims abstract description 10
- 239000012043 crude product Substances 0.000 claims abstract description 10
- 239000012074 organic phase Substances 0.000 claims abstract description 10
- 239000012071 phase Substances 0.000 claims abstract description 10
- XKXIQBVKMABYQJ-UHFFFAOYSA-M tert-butyl carbonate Chemical group CC(C)(C)OC([O-])=O XKXIQBVKMABYQJ-UHFFFAOYSA-M 0.000 claims abstract description 9
- 238000003756 stirring Methods 0.000 claims abstract description 8
- 239000003960 organic solvent Substances 0.000 claims abstract description 5
- MALOBWMOORWUQW-UHFFFAOYSA-N 4h-pyran-3-one Chemical class O=C1COC=CC1 MALOBWMOORWUQW-UHFFFAOYSA-N 0.000 claims abstract 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 34
- 239000003446 ligand Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 claims description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- VOLMSPGWNYJHQQ-UHFFFAOYSA-N Pyranone Natural products CC1=C(O)C(=O)C(O)CO1 VOLMSPGWNYJHQQ-UHFFFAOYSA-N 0.000 claims description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 2
- DFFDSQBEGQFJJU-UHFFFAOYSA-M butyl carbonate Chemical group CCCCOC([O-])=O DFFDSQBEGQFJJU-UHFFFAOYSA-M 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 229930182475 S-glycoside Natural products 0.000 abstract description 16
- 150000003569 thioglycosides Chemical class 0.000 abstract description 14
- 239000000047 product Substances 0.000 abstract description 11
- 238000010276 construction Methods 0.000 abstract description 7
- 235000000346 sugar Nutrition 0.000 abstract description 7
- 238000007306 functionalization reaction Methods 0.000 abstract description 2
- 150000008163 sugars Chemical class 0.000 abstract 1
- 238000005481 NMR spectroscopy Methods 0.000 description 20
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 19
- 238000003786 synthesis reaction Methods 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 239000000543 intermediate Substances 0.000 description 10
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 238000010586 diagram Methods 0.000 description 7
- 229930014626 natural product Natural products 0.000 description 7
- 229910052763 palladium Inorganic materials 0.000 description 7
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 125000003396 thiol group Chemical group [H]S* 0.000 description 5
- 150000003573 thiols Chemical class 0.000 description 5
- 238000006685 Achmatowicz rearrangement reaction Methods 0.000 description 4
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000004611 spectroscopical analysis Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- USFPINLPPFWTJW-UHFFFAOYSA-N tetraphenylphosphonium Chemical compound C1=CC=CC=C1[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 USFPINLPPFWTJW-UHFFFAOYSA-N 0.000 description 4
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical compound O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- UXRZLDREKITWRO-UHFFFAOYSA-N P(c1ccccc1)c1ccccc1.CC1(C)c2ccccc2Oc2ccccc12 Chemical compound P(c1ccccc1)c1ccccc1.CC1(C)c2ccccc2Oc2ccccc12 UXRZLDREKITWRO-UHFFFAOYSA-N 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-MICDWDOJSA-N 1-deuteriopropan-2-one Chemical compound [2H]CC(C)=O CSCPPACGZOOCGX-MICDWDOJSA-N 0.000 description 2
- VREFDQNWPNDZEX-UHFFFAOYSA-N 3,6-Dihydro-2H-pyran-2-one Chemical class O=C1CC=CCO1 VREFDQNWPNDZEX-UHFFFAOYSA-N 0.000 description 2
- CTUFQKDQCZIHMS-UHFFFAOYSA-N 4-bromo-2-phenylbenzenethiol Chemical compound SC1=CC=C(Br)C=C1C1=CC=CC=C1 CTUFQKDQCZIHMS-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 description 1
- BDFAOUQQXJIZDG-UHFFFAOYSA-N 2-methylpropane-1-thiol Chemical compound CC(C)CS BDFAOUQQXJIZDG-UHFFFAOYSA-N 0.000 description 1
- FTBCOQFMQSTCQQ-UHFFFAOYSA-N 4-bromobenzenethiol Chemical compound SC1=CC=C(Br)C=C1 FTBCOQFMQSTCQQ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ZUKPVRWZDMRIEO-VKHMYHEASA-N L-cysteinylglycine Chemical compound SC[C@H]([NH3+])C(=O)NCC([O-])=O ZUKPVRWZDMRIEO-VKHMYHEASA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 229960005207 auranofin Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 150000001975 deuterium Chemical group 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- ICGWWCLWBPLPDF-UHFFFAOYSA-N furan-2-ol Chemical class OC1=CC=CO1 ICGWWCLWBPLPDF-UHFFFAOYSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Saccharide Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
一类6‑芳/烷硫基‑2H‑吡喃‑3‑酮类化合物的合成方法,将叔丁基碳酸酯取代的二氢吡喃酮类化合物、吡喃酮受体和催化剂加入到有机溶剂中,室温搅拌,TLC检测反应进程,当叔丁基碳酸酯取代的二氢吡喃酮化合物原料完全消失后,终止反应,萃取收集有机相,减压蒸馏除去溶剂得到粗产物,然后采用石油醚/乙酸乙酯溶液作为流动相进行柱层析得到6‑芳/烷硫基‑2H‑吡喃酮类化合物。所产生的6‑芳/烷硫基‑2H‑吡喃‑3‑酮类化合物,进一步通过还原和双羟基化便可得到硫糖苷的产物,且此方法相较于前人已报道的硫糖苷构建方法而言,可以预料之外地同时进行天然糖以及非天然糖高效构建,对6‑芳/烷硫基‑2H‑吡喃‑3‑酮进行简单官能团化应用即可实现。
Description
技术领域
本发明提供一类6-芳/烷硫基-2H-吡喃-3-酮类化合物的合成方法及其在构建硫糖苷中的应用,属于有机合成技术领域。
背景技术
Achmatowicz重排反应是一类能将官能团化的呋喃醇转化为相应的2,6-二氢-吡喃酮、二氢吡啶酮等重要的化工中间体的环扩张反应。近些年来,Achmatowicz反应在药物合成以及天然产物合成中受到广泛的关注。该反应生成的化工中间体2,6-二氢-吡喃酮可作为重要的分子骨架,为之后的Kishi还原反应,基于二氢吡喃酮类化合物的糖基化反应,[5+2]环加成反应以及双酮化反应奠定重要的合成基础,也被广泛用于复杂天然产物的全合成中,为天然产物的合成以及活性探究提供新的思路。
基于二氢吡喃酮类化合物的糖基化反应更好地说明了Achmatowicz重排反应是从头合成己糖最方便的方法之一。但是目前大家的研究方向仅限于以此方法合成二氢吡喃酮的原料,将其应用于天然产物合成和结构修饰,氧糖苷,碳糖苷以及氮糖苷类化合物的立体选择性合成,硫糖苷类化合物的研究较少。
近年来已开发多种硫糖苷类药物例如金诺芬、林可霉素等,除此之外报道的各种硫糖苷化合物以及其结构类似物的生物活性,有力地证明了这类化合物是潜在的具有医疗效果的目标化合物。但是这类化合物在合成过程中大都采用Lewis酸催化,存在反应条件苛刻,底物范围受限的缺点;还有采用过渡金属催化,存在立体选择性较差的问题。一般硫苷的合成需要采用立体选择性固定的手性原料,合成底物范围较窄,严重受限。
发明内容
针对上述技术问题,本发明提供一类6-芳/烷硫基-2H-吡喃-3-酮类化合物的合成方法及其在构建硫糖苷中的应用,本发明使用容易离去的叔丁基碳酸酯取代的Achmatowicz重排反应的产物二氢吡喃酮基碳酸酯作为供体,含有巯基的化合物为受体,在温和的条件下,通过钯催化合成6-芳/烷硫基吡喃酮类化合物(所述反应通式如下)。该方法中催化剂,配体以及溶剂都是不可缺少的关键条件,对反应的速率及立体选择性起着至关重要的作用。此外由于此反应是催化剂与配体发生配位,然后与吡喃酮的烯键形成Pdπ-烯丙基中间体,然后与受体反应,脱去叔丁醇和CO2形成产物。因此该方法相较于其他方法而言,底物范围广、高效,条件温和且具有优良的区域选择性和高立体选择性。而且目标产物进行还原、双羟基化得到1-硫代的醛糖产物,为之后硫糖苷的研究提供新的方向。
包括如下步骤:将叔丁基碳酸酯取代的二氢吡喃酮类化合物、吡喃酮受体和催化剂加入到有机溶剂中,室温搅拌,TLC检测反应进程,当叔丁基碳酸酯取代的二氢吡喃酮化合物原料完全消失后,终止反应,萃取收集有机相,减压蒸馏除去溶剂得到粗产物,然后采用石油醚/乙酸乙酯溶液作为流动相进行柱层析得到6-芳/烷硫基-2H-吡喃酮类化合物,反应式如下
所述的R基团包括-H、烷基或取代烷基;所述的烷基包括C1-C6的支链烷基或C1-C6的直链烷基;所述的取代烷基包括C1-C6的支链烷基或C1-C6的直链烷基上被-OPG取代得到的任意一种取代烷基;
R1为硫酚、硫醇、含巯基的多肽、硫糖、或含巯基的天然产物类似物中的任意一种。
含巯基的多肽包括半胱氨酸、谷胱甘肽、半胱氨酸-丙氨酸,半胱氨酸-甘氨酸,半胱氨酸-苯丙氨酸、半胱氨酸-色氨酸、半胱氨酸-苯丙氨酸-色氨酸;
硫糖包括含巯基的葡萄糖、半乳糖、阿拉伯糖的单糖;
含巯基的天然产物类似物包括雌酮,薄荷醇、丹皮酚、姜酮以及根皮素的巯基类似物。
所述的催化剂、配体、二氢吡喃酮类化合物、受体的摩尔比为0.002-0.005:0.005-0.01:1:1-1.5。
所述的有机溶剂包括DCM、THF、Toluene、MeCN等中的任意一种。
综述实验结果得到了本发明最佳实验条件为Pd(PPh3)4作为催化剂、Xantphos作为膦配体、DCM作为溶剂,室温下搅拌反应。
叔丁基碳酸酯取代的Achmatowicz重排反应的产物二氢吡喃酮基碳酸酯作为供体,含有巯基的化合物为受体,在温和的条件下,通过钯催化合成6-芳/烷硫基吡喃酮类化合物(所述反应通式如下),该方法具有优良的区域选择性和高立体选择性。
该方法中催化剂,配体以及溶剂都是不可缺少的关键条件,对反应的速率及立体选择性起着至关重要的作用。此外由于此反应是催化剂与配体发生配位,然后与吡喃酮的烯键形成Pd-π-烯丙基中间体,然后与受体反应,脱去叔丁醇和CO2形成产物。因此该方法相较于其他方法而言,底物范围广、高效,条件温和且具有优良的区域选择性和高立体选择性。除此之外,目标产物进行还原、双羟基化即可快速得到结构多样,立体选择性高的目标硫糖苷产物。
本发明的又一技术方案是将所述制备得到的6-芳/烷硫基-2H-吡喃-3-酮类化合物在构建硫糖苷中的应用。
所述的在构建硫糖苷中的应用包括如下步骤:
(1)以6-芳/烷硫基-2H-吡喃-3-酮类化合物为原料,二氯甲烷为溶剂,加入NaBH4,CeCl3的甲醇溶液,TLC检测反应进程,当原料完全消失后,终止反应,萃取收集有机相,减压蒸馏除去溶剂得到粗产物,然后采用石油醚/乙酸乙酯溶液作为流动相进行柱层析获得中间体6-芳/烷硫基-2H-吡喃-3-醇类化合物;
(2)以中间体6-芳/烷硫基-2H-吡喃-3-醇类化合物为原料,加入二氯甲烷溶解,加入过量的N-甲基吗啉-N-氧化物的(50%,w/w)溶液(指N-甲基吗啉-N-氧化物以一定比例(50%,w/w)溶于水即成无色透明的N-甲基吗啉-N-氧化物水溶液),催化剂OsO4,TLC检测反应进程,当原料完全消失后,终止反应,萃取收集有机相,减压蒸馏除去溶剂得到粗产物,然后采用石油醚/乙酸乙酯溶液作为流动相进行柱层析获得硫糖苷。
所述的步骤(1)中,6-芳/烷硫基-2H-吡喃-3-酮类化合物的摩尔浓度为0.1-0.5mmol;CeCl3的甲醇溶液的摩尔浓度为0.3-0.6M;NaBH4的的摩尔浓度为0.05-0.2mmol;反应温度为-50~-85℃;反应温度为-50~-85℃;
步骤(2)中,中间体6-芳/烷硫基-2H-吡喃-3-醇类化合物的摩尔浓度为0.1-0.5mmol;N-甲基吗啉-N-氧化物的的量为0.15-0.75mmol;OsO4催化剂的添加量为中间体6-芳/烷硫基-2H-吡喃-3-醇类化合物的摩尔量的5-20%;反应温度为-10~10℃。
本发明所产生的6-芳/烷硫基-2H-吡喃-3-酮类化合物,之后通过还原和双羟基化便可得到硫糖苷的产物,且此方法相较于前人已报道的硫糖苷构建方法(受限于天然糖)而言,可以预料之外地同时进行天然糖以及非天然糖高效构建,对6-芳/烷硫基-2H-吡喃-3-酮进行简单官能团化应用即可实现,在药物研发以及生物活性研究中具有更广泛应用。
附图说明
图1为(2R,6R)-6-((4-溴苯基)硫代)-2-甲基-2H-吡喃-3(6H)-酮的1H NMR。
图2为(2R,6R)-6-((4-溴苯基)硫代)-2-甲基-2H-吡喃-3(6H)-酮的13C NMR。
图3为(2R,6R)-6-(异丁硫基)-2-甲基-2H-吡喃-3(6H)-酮的1H NMR。
图4为(2R,6R)-6-(异丁硫基)-2-甲基-2H-吡喃-3(6H)-酮的13C NMR。
图5为(2R,6R)-6-((4-溴苯基)硫代)-2-乙基-2H-吡喃-3(6H)-酮的1H NMR。
图6为(2R,6R)-6-((4-溴苯基)硫代)-2-乙基-2H-吡喃-3(6H)-酮的13C NMR。
图7为1-(丁基磺酰基)-α-D-鼠李糖的1H NMR。
图8为1-(丁基磺酰基)-α-D-鼠李糖的13C NMR。
具体实施方式
本实施例所用到的实验试剂包括如下:
四三苯基膦钯(麦克林)、二氯甲烷(分析纯,国药集团欧化学试剂公司)、石油醚(沸程60-90℃,国药集团化学试剂公司)、乙酸乙酯(分析纯,国药集团化学试剂公司)、无水硫酸钠(分析纯,天津福晨化学试剂厂)、氘代氯仿(氘原子含量99.8%,TMS含量0.03%V/V,10*0.5mL/盒,瑞士ARMAR公司);核磁管(5mm 100/pk 2ST500-8,美国Norell公司)。
本实施例所用到的实验仪器包括如下:
2XZ-4型双极旋片式真空泵(上海华盛真空设备厂)、DZF-6020型真空干燥箱(上海齐欣科学仪器有限公司)、SHB-IIIA循环水式多用途真空泵(上海豫康科教仪器设备有限公司)、ZNCL-B 180型平板磁力搅拌器(郑州市亚荣仪器有限公司)、EYELA SB-1100旋转蒸发仪(上海埃朗仪器有限公司)、FTX-FA210分析天平(华志电子科技有限公司)、DLSB-5/30低温循环槽(上海东玺制冷仪器设备公司)、GZX-9240MBE数显鼓风干燥箱(上海博迅实业有限公司医疗设备厂)、ZF-6型三用紫外分析仪(上海嘉鹏科技有限公司)、BrukerAV 400MHz核磁共振仪(瑞士Bruker公司)。
实施例1
以(2R,6R)-叔丁基2-(6-甲基5-氧代-5,6-二氢-2H-吡喃基)碳酸酯为例,采取不同催化剂、配体、溶剂的优化实验方案,具体如下:
注:所有试验采用0.1mmol 6-叔丁基(2R,6R)-(6-甲基5-氧代-5,6-二氢-2H-吡喃基)碳酸酯与0.11mmol对溴苯硫酚,2mol%Pd催化剂,5mol%膦配体在2mL溶剂中室温下搅拌反应;分离产率;立体选择性由核磁氢谱测得>=20:1。
本发明的技术方案对反应条件进行了筛选优化。反应条件筛选试验表明,没有配体或者催化剂反应都不能得到目标产物(entries 1-2),在DCM做溶剂的条件下,首先对催化剂进行筛选(entries 3-6)。发现Pd(PPh3)4是最优催化剂。接下来,对配体进行了优化(entries 6-9),优化结果表明,Xantphos作为膦配体时,才会生成目标产物。最后筛选了反应溶剂(entries 10-12),发现DCM是最优溶剂。
综述实验结果,得到了6-芳/烷硫基吡喃酮类化合物的最优反应条件确定最优条件为(entry 6),以Pd(PPh3)4为催化剂、Xantphos作为膦配体、二氯甲烷为反应溶剂。且化合物的构型已经通过高分辨率质谱,核磁共振氢谱、碳谱和二维谱确证。
在上述路线的情况下,本发明以6-叔丁基(2R,6R)-(6-甲基5-氧代-5,6-二氢-2H-吡喃基)碳酸酯为原料制备了(2R,6R)-6-((4-溴苯基)硫代)-2-甲基-2H-吡喃-3(6H)-酮类化合物,技术路线如下:
在四三苯基膦钯(Pd(PPh3)4,3.0mg,0.0026mmol),4,5-双(二苯基膦)-9,9-二甲基氧杂蒽(Xantphos,3.8mg,0.00657mmol)和6-叔丁基(2R,6R)-(6-甲基5-氧代-5,6-二氢-2H-吡喃基)碳酸酯(0.1315mmol)中加入2mL的二氯甲烷和受体(对溴苯硫酚)(0.1446mmol)。室温搅拌,TLC检测反应进程,当碳酸酯原料完全消失后,终止反应,萃取收集有机相,减压蒸馏除去溶剂得到粗产物,然后采用石油醚/乙酸乙酯溶液作为流动相进行柱层析获得(2R,6R)-6-((4-溴苯基)硫代)-2-甲基-2H-吡喃-3(6H)-酮(收率为80%)。
实施例2
在上述路线的情况下,本发明还以6-叔丁基(2R,6R)-(6-甲基5-氧代-5,6-二氢-2H-吡喃基)碳酸酯为原料制备了(2R,6R)-6-(异丁硫基)-2-甲基-2H-吡喃-3(6H)-酮,技术路线如下:
在四三苯基膦钯(Pd(PPh3)4,3.0mg,0.0026mmol),4,5-双(二苯基膦)-9,9-二甲基氧杂蒽(Xantphos,3.8mg,0.00657mmol)和6-叔丁基(2R,6R)-(6-甲基5-氧代-5,6-二氢-2H-吡喃基)碳酸酯(0.1315mmol)中加入2mL的二氯甲烷和受体(异丁硫醇)(0.1446mmol)。室温搅拌,TLC检测反应进程,当碳酸酯原料完全消失后,终止反应,萃取收集有机相,减压蒸馏除去溶剂得到粗产物,然后采用石油醚/乙酸乙酯溶液作为流动相进行柱层析获得(2R,6R)-6-(异丁硫基)-2-甲基-2H-吡喃-3(6H)-酮(收率为83%)。
实施例3
在上述路线的情况下,本发明以6-叔丁基(2R,6R)-(6-乙基-5-氧代-5,6-二氢-2H-吡喃基)碳酸酯为原料制备了(2R,6R)-6-((4-溴苯基)硫代)-6-乙基-2H-吡喃-3(6H)-酮化合物,技术路线如下:
在四三苯基膦钯(Pd(PPh3)4,3.0mg,0.0026mmol),4,5-双(二苯基膦)-9,9-二甲基氧杂蒽(Xantphos,3.8mg,0.00657mmol)和6-叔丁基(2R,6R)-(6-乙基-5-氧代-5,6-二氢-2H-吡喃基)碳酸酯(0.1315mmol)中加入2mL的二氯甲烷和吡喃酮受体(对溴苯硫酚)(0.1446mmol)。室温搅拌,TLC检测反应进程,当碳酸酯原料完全消失后,终止反应,萃取收集有机相,减压蒸馏除去溶剂得到粗产物,然后采用石油醚/乙酸乙酯溶液作为流动相进行柱层析获得(2R,6R)-6-((4-溴苯基)硫代)-2-乙基-2H-吡喃-3(6H)-酮(收率为81%)。
实施例4
在上述路线的情况下,本发明还以(2R,6R)-6-(丁硫基)-2-甲基-2H-吡喃-3(6H)-碳酸酯为原料,合成了1-(丁基磺酰基)-α-D-鼠李糖,技术路线如下:
以(2R,6R)-6-(丁硫基)-2-甲基-2H-吡喃-3(6H)-酮(0.10mmol)为原料,加入2mL的二氯甲烷溶解,-78℃下加入NaBH4(0.12mmol),0.4M CeCl3的甲醇溶液,TLC检测反应进程,当碳酸酯原料完全消失后,终止反应,萃取收集有机相,减压蒸馏除去溶剂得到粗产物,然后采用石油醚/乙酸乙酯溶液作为流动相进行柱层析获得中间体1。
以中间体1(0.10mmol)为原料,加入2mL的二氯甲烷溶解,0℃下加入0.15mmol的4-甲基吗啉-N-氧化物的1:1(w/w)溶液,催化量为(10mol%)的OsO4,TLC检测反应进程,当原料完全消失后,终止反应,萃取收集有机相,减压蒸馏除去溶剂得到粗产物,然后采用石油醚/乙酸乙酯溶液作为流动相进行柱层析获得1-(丁基磺酰基)-α-D-鼠李糖(产率75%)。
硫酚类4-羰基-2,3-烯糖(参考实施例1的条件得到)
硫醇类4-羰基-2,3-烯糖(参考实施例2的条件得到)
氨基酸及多肽类4-羰基-2,3-烯糖(参考实施例2的条件得到)
二糖类(参考实施例2的条件得到)
含巯基的天然产物类似物4-羰基-2,3-烯糖(参考实施例2的条件得到)
不同糖型的4-羰基-2,3-烯糖(参考实施例3的条件得到)
应用于硫代糖苷合成的底物范围(参考实施例4的条件得到)
以上所述的底物生成的6-芳/烷硫基-2H-吡喃-3-酮类化合物均可参考实施例4得到相应的硫糖苷类产物如下:
核磁共振波谱数据
(2R,6R)-6-((4-bromophenyl)thio)-2-methyl-2H-pyran-3(6H)-one
1H NMR(400MHz,Chloroform-d)δ7.51–7.44(m,2H),7.44–7.37(m,2H),7.07(dd,J=10.1,3.9Hz,1H),6.10(dd,J=10.1,1.4Hz,1H),5.88(dd,J=3.9,1.3Hz,1H),4.88(q,J=6.7Hz,1H),1.44(d,J=6.7Hz,3H).
13C NMR(100MHz,Chloroform-d)δ196.0,144.6,133.3,132.3,126.6,122.3,82.9,71.2,15.0.。
(2R,6R)-6-(isobutylthio)-2-methyl-2H-pyran-3(6H)-one
1H NMR(400MHz,Chloroform-d)δ7.00(dd,J=10.1,3.9Hz,1H),6.03(dd,J=10.0,1.4Hz,1H),5.66(dd,J=3.9,1.4Hz,1H),4.77(q,J=6.7Hz,1H),2.74–2.53(m,2H),1.97–1.85(m,1H),1.41(d,J=6.7Hz,3H),1.04(d,J=6.7Hz,6H).
13C NMR(100MHz,Chloroform-d)δ196.5,146.1,125.9,79.9,70.4,41.3,28.9,21.93,21.8,14.9.。
(2R,6R)-6-(isobutylthio)-2-ethyl-2H-pyran-3(6H)-one
/>
1H NMR(400 MHz,Chloroform-d)δ7.53–7.40(m,4H),7.09(dd,J=10.0,3.9 Hz,1H),6.12(dd,J=10.0,1.2 Hz,1H),5.93(dd,J=3.9,1.3 Hz,1H),4.70(dd,J=7.9,3.6Hz,1H),2.16–2.01(m,1H),1.88–1.74(m,1H),1.01(t,J=7.4 Hz,3H).
13C NMR(100 MHz,Chloroform-d)δ195.6,144.5,133.4,133.3,132.2,127.0,122.2,82.9,77.375.9,22.6,9.6.。
1-(butylsulfonyl)-α-D-rhamnoside
1H NMR(400MHz,Acetone-d6)δ4.85(d,J=1.1Hz,1H),4.49(dd,J=3.8,1.3Hz,1H),4.17(dq,J=9.3,6.2Hz,1H),3.90(dd,J=9.3,3.7Hz,1H),3.49(t,J=9.3Hz,1H),3.17–3.12(m,2H),1.81–1.68(m,2H),1.53–1.25(m,2H),1.26(d,J=6.1Hz,3H),0.94(t,J=7.3Hz,3H).
13C NMR(100MHz,Acetone-d6)δ92.5,74.4,72.6,72.5,66.6,50.6,24.4,22.4,18.6,13.9.。
Claims (2)
1.一类2H-吡喃-3-酮类化合物的合成方法,其特征在于,包括如下步骤:
将叔丁基碳酸酯取代的二氢吡喃酮类化合物、吡喃酮受体、催化剂和配体加入到有机溶剂中,室温搅拌,TLC检测反应进程,当叔丁基碳酸酯取代的二氢吡喃酮化合物原料完全消失后,终止反应,萃取收集有机相,减压蒸馏除去溶剂得到粗产物,然后采用石油醚/乙酸乙酯溶液作为流动相进行柱层析得到2H-吡喃-3-酮类化合物,反应式如下:
;
其中,叔丁基碳酸酯取代的二氢吡喃酮类化合物为:
;
吡喃酮受体选自:
;
2H-吡喃-3-酮类化合物选自:
、/>;
所述的催化剂选自Pd2(dba)3、Pd(OAc)2、Pd(MeCN)2Cl2、Pd(PPh3)4中的任意一种;
所述的配体选自Xantphos、t-BuXphos、DPEPhos、JohnPhos中的任意一种;
所述的有机溶剂选自DCM、THF、甲苯或 MeCN 中的任意一种。
2.根据权利要求1所述的2H-吡喃-3-酮类化合物的合成方法,其特征在于,所述的催化剂、配体、叔丁基碳酸酯取代的二氢吡喃酮类化合物、吡喃酮受体的摩尔比为0.002-0.005:0.005-0.01:1:1-1.5。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410069039.2A CN117986219A (zh) | 2022-08-22 | 2022-08-22 | 一种6-芳/烷硫基-2h-吡喃-3-酮类化合物制备硫糖苷的方法 |
CN202211007274.4A CN115368332B (zh) | 2022-08-22 | 2022-08-22 | 6-芳/烷硫基-2h-吡喃-3-酮类化合物的合成方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211007274.4A CN115368332B (zh) | 2022-08-22 | 2022-08-22 | 6-芳/烷硫基-2h-吡喃-3-酮类化合物的合成方法及其应用 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410069039.2A Division CN117986219A (zh) | 2022-08-22 | 2022-08-22 | 一种6-芳/烷硫基-2h-吡喃-3-酮类化合物制备硫糖苷的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115368332A CN115368332A (zh) | 2022-11-22 |
CN115368332B true CN115368332B (zh) | 2024-03-12 |
Family
ID=84068735
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211007274.4A Active CN115368332B (zh) | 2022-08-22 | 2022-08-22 | 6-芳/烷硫基-2h-吡喃-3-酮类化合物的合成方法及其应用 |
CN202410069039.2A Pending CN117986219A (zh) | 2022-08-22 | 2022-08-22 | 一种6-芳/烷硫基-2h-吡喃-3-酮类化合物制备硫糖苷的方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410069039.2A Pending CN117986219A (zh) | 2022-08-22 | 2022-08-22 | 一种6-芳/烷硫基-2h-吡喃-3-酮类化合物制备硫糖苷的方法 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN115368332B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1906203A (zh) * | 2003-12-23 | 2007-01-31 | 普罗吉恩工业有限公司 | 葡糖胺基聚糖(gag)模拟物 |
WO2011050323A1 (en) * | 2009-10-22 | 2011-04-28 | The Washington University | Compounds and methods for treating bacterial infections |
CN112279880A (zh) * | 2019-07-23 | 2021-01-29 | 四川大学 | 一种新的糖基供体、硫苷化合物及其制备方法 |
CN112672765A (zh) * | 2018-06-29 | 2021-04-16 | 格莱科斯生物医药公司 | 结合物 |
-
2022
- 2022-08-22 CN CN202211007274.4A patent/CN115368332B/zh active Active
- 2022-08-22 CN CN202410069039.2A patent/CN117986219A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1906203A (zh) * | 2003-12-23 | 2007-01-31 | 普罗吉恩工业有限公司 | 葡糖胺基聚糖(gag)模拟物 |
WO2011050323A1 (en) * | 2009-10-22 | 2011-04-28 | The Washington University | Compounds and methods for treating bacterial infections |
CN112672765A (zh) * | 2018-06-29 | 2021-04-16 | 格莱科斯生物医药公司 | 结合物 |
CN112279880A (zh) * | 2019-07-23 | 2021-01-29 | 四川大学 | 一种新的糖基供体、硫苷化合物及其制备方法 |
Non-Patent Citations (3)
Title |
---|
AU Song等.Divergent de novo synthesis of all eight stereoisomers of 2,3,6-trideoxyhexopyranosides and their oligomers.《Chemical Communications》.2015,第51卷(第98期),17475-17478. * |
De Novo Synthesis of Oligosaccharides Using a Palladium-Catalyzed Glycosylation Reaction;Ravula Satheesh Babu 等;《Journal of the American Chemical Society 》;20040923;第126卷(第11期);3428-3429 * |
Grzegorz等.Synthesis of 6-Alkoxy-2,3-dihydro-6H-pyran-3-ones from the 6-Acyloxy Derivatives.《Synthesis》.1979,(第5期),364-365. * |
Also Published As
Publication number | Publication date |
---|---|
CN115368332A (zh) | 2022-11-22 |
CN117986219A (zh) | 2024-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109575093B (zh) | 一种烯烃化雌激素类化合物及其制备与应用 | |
CN114014872A (zh) | 青蒿琥酯衍生物及其制备方法和应用 | |
AU2016322373A1 (en) | Phosphoramidate compound and preparation method and crystal thereof | |
CN113603730B (zh) | 硼酸三酯为糖受体选择性合成氧糖苷或2-脱氧糖的方法 | |
CN115368332B (zh) | 6-芳/烷硫基-2h-吡喃-3-酮类化合物的合成方法及其应用 | |
CN111995638B (zh) | 一类3-硫-1-烯糖类化合物的合成方法 | |
EP1301499A1 (en) | Stable isotope labeling of paclitaxel | |
CN112979665B (zh) | 一种灰黄霉素施密特重排衍生物及其制备方法 | |
CN113061077B (zh) | α,α-二氘代醇类化合物、氘代药物及其制备方法 | |
Zheng et al. | Gold-catalyzed synthesis of α-D-glucosides using an o-ethynylphenyl β-D-1-thioglucoside donor | |
CN108440466B (zh) | 5-芳基-3-(2-氨基磺酸酯基-5-取代亚苄基)丁烯内酯化合物及制备方法、应用 | |
CN113372353A (zh) | 一种二氟烷基化的二氢呋喃喹啉酮衍生物及其制备方法 | |
CN115466294A (zh) | 一类2-脱氧硫糖苷的高立体选择性合成方法 | |
CN116874530A (zh) | 一种(3r)-3-硫代糖的合成方法 | |
CN112898253B (zh) | 一种合成含手性叔醇结构的3-香豆冉酮类化合物的方法 | |
Yuan et al. | Synthesis and biological activity of C-6 and C-7 modified paclitaxels | |
CN111454184B (zh) | 化合物及其制备方法、医药中间体及其应用 | |
CN103508999A (zh) | 马沙骨化醇的合成中间体及其制备方法和用途 | |
CN114380840B (zh) | 艾日布林的合成 | |
CN108440242A (zh) | 一种高活性手性炔醇(s,e)-1,9-二烯-4,6-二炔-3-十八醇的合成方法 | |
CN102838633B (zh) | 一种制备γ-氧代膦酸酯的方法 | |
CN108440552B (zh) | 一种高活性大环内酯Ivorenolide B的合成方法 | |
CN111517934B (zh) | γ-烯基酮及其合成方法 | |
Andrews et al. | Synthesis and characterisation of a chiral lanthanoid cluster with an unusually exposed cubane core via concomitant deesterification of ethyl acetate | |
CN117924231A (zh) | 酯类化合物、二芳基丙烯酸类混合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |